Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Only a licensed healthcare provider can determine whether a medication is safe based on your individual medical profile
Food and Drug Administration approved Wegovy (semaglutide) injection (2.4 mg once weekly) for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), for use in addition to a reduced calorie diet and increased physical activity (Dated June 4, 2021)
The hassle-free online evaluations and home delivery of medication simplify treatment access, and individuals comfortable with daily tablets or regular injections can find viable options here
Overall, about 140,400 patients with obesity were prescribed the medications in 2024 in Massachusetts, the Globe has reported
For example, in clinical trials of semaglutide 2.4 mg (Wegovy), nausea occurred in approximately 44% of patients, while rates for tirzepatide and other GLP-1s vary: Nausea : Often described as mild queasiness, particularly after eating, though some patients experience more pronounced nausea Bloating and abdominal fullness : A sensation of delayed digestion or food sitting heavily in the stomach Changes in bowel habits : Constipation affects approximately 15-30% of patients (varying by medication and dose), while some experience diarrhea or alternating patterns [1] [4] Decreased appetite : Beyond simple fullness, many report a fundamental shift in food thoughts, with reduced cravings and less mental preoccupation with eating Some patients report fatigue or low energy , particularly during the initial weeks
They should be compared clearly and without implying that a compounded drug is an FDA-approved generic or identical copy
.jpg)